Bibliografía

1. National Institute of Health. Consensus Development Conference Statement: Osteoporosis Prevention, Diagnosis and Therapy. Bethesda, Md, National Institute of Health; 2000:1-29.
2. Ralston SH. The genetics of osteoporosis. QJM; 90: 247, 1997.
3. Kiel DP, Myers RH, Cupples LA. The BsmI vitamin D receptor restriction fragment lenght polymorphism (bb) influences the effect of calcium intake on bone mineral density. J Bone Miner Res; 12: 1049, 1997.
4. McGuidan FEA, Reid DM, Ralston SH. Susceptibility to osteoporotic fracture is determined by allelic variation at the Sp1 site, rather than other polymorphic sites at the COL1A1 locus. Osteoporos Int 11:338-342, 2000.
5. Heegaard A, Jorgensen HL, Vestergaard AW, Hassager C, Ralston SH. Lack of influence of collagen type 1alpha1 Sp1 binding site polymorphism on the rate of bone loss in a cohort of postmenopausal Danish women followed 18 years. Calcif Tissue Int 66:409-413, 2000.
6. Chapuy MC, Arlot ME, Duboeuf F. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: 1637, 1992.
7. Cummings SR, Browner WS. Bauer D for the Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339: 733, 1998.
8. Hughes DE, Dai I, Tiffee JC. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-???Nat Med 2: 1132, 1996.
9. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrionol Metab. 80: 3351, 1995.
10. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PWF, Felson DT. Association of hypogonadism and estradiol levels with bone mineral density in erderly men from the Framingham study. Ann Int Med 133: 951-963, 2000.
11. Slemenda C, Longscope C, Peacock M. Sex steroids, bone mass and bone loss. J Clin Invest 97:14, 1996.
12. Gimeno EJ, Munoz-Torres M, Escobar-Jimenez F. Identification of metabolic bone disease in patients with endogenous hyperthyroidism. Role of biological markers of bone turnover. Calcif Tissue Int. 61: 370, 1997.
13. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 993-1000, 2000.
14. Rojas E, Carlini R, Clesca P, Arminio A, Weisinger JR, Hruska KA, Bellorin-Font E. Kidney Int. The pathogenesis of post-transplant osteodystrophy as detected by alterations in bone remodeling. 11: 570, 2000.
15. Zheng SX, Vrintis Y, Lopez M. Increase in cytokine production (IL-1-beta, IL-6, TNF alpha but not INF gamma, GM-csf or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 26: 63, 1997.
16. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345-57, 1999.
17. Roux S, Orcel P. Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res. 2: 451-456, 2000.
18. Lories RJ, Luyteen FP. Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets.
    Clin Rheumatol.; 20:3-9, 2001.